(Q47996841)

English

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer

scientific article published in March 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

author name string

Anne-Sofie Schrohl

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Ib Jarle Christensen

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Anders N Pedersen

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Vibeke Jensen

4

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Henning Mouridsen

5

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Gillian Murphy

6

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

John A Foekens

7

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Nils Brunner

8

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Mads Nikolaj Holten-Andersen

9

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Molecular & Cellular Proteomics

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

164-172

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

How matrix metalloproteinases regulate cell behavior

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

New functions for the matrix metalloproteinases in cancer progression

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1.

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer.

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells.

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Complex roles of tissue inhibitors of metalloproteinases in cancer

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M300019-MCP200

21 January 2018

Identifiers

10.1074/MCP.M300019-MCP200

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

release_crrhenapzzbizpbyiq4daw746q

1 reference

https://api.fatcat.wiki/v0/release/crrhenapzzbizpbyiq4daw746q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/12672830

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47996841&oldid=2180976837"